NeuroRx
NeuroRx Research is a Montreal-based imaging contract research organization that provides centralized MRI analysis services for multicenter clinical trials, primarily in multiple sclerosis and neurological diseases, serving pharmaceutical sponsors globally and operating as a subsidiary of Clario since 2025.
- Company typePrivate
- Founded2002
- HeadquartersMontréal, Canada
- Headcount101–250
- GTM typeB2B
- OfferingServices
What NeuroRx does
NeuroRx Research is an imaging Contract Research Organization headquartered in Montreal, Canada, that provides centralized MRI analysis services for multicenter clinical trials worldwide. Founded in 2002, the company focuses primarily on multiple sclerosis and other neurological diseases, serving pharmaceutical sponsors running drug development programs. Its core technology stack combines 3D volumetric image analysis (rather than slice-by-slice review), automated segmentation with expert human supervision, inhomogeneity correction and co-registration, and proprietary tools including the NeuroRx Scan Tracking Tool (NTT) for trial logistics and the NeuroRx Trial-specific Database (NFD) for validated data management. NeuroRx also operates non-conventional MRI capabilities in magnetization transfer imaging (MTR) and magnetic resonance spectroscopy (MRS). The company holds an active operating footprint spanning 60+ countries and runs in a fully ICH-GCP and 21CFR Part 11 compliant environment, with GDPR-aligned data handling and storage in Quebec.
The company's commercial model is project-based professional services: revenue is generated through contracted engagements with pharmaceutical sponsors, where NeuroRx manages the full MRI workflow including protocol assistance, manual and form provision, site setup and supervision, image acquisition, analysis, reporting, and result transfers. Pricing is negotiated per trial rather than published, consistent with enterprise B2B CRO economics. NeuroRx sells primarily through direct enterprise relationships with pharma R&D decision-makers, supplemented by content marketing via its corporate website and participation in industry webinars alongside peers such as Clario. The buyer segment is narrow — pharmaceutical sponsors with active neurological pipelines — and engagement size is tied to trial phase, duration, and site count. Since 2025, NeuroRx has operated as a subsidiary of Clario following acquisition, with its MS imaging capabilities now positioned within Clario's neuroscience therapeutic area; Clario itself is the subject of a pending $8.9 billion bid from Thermo Fisher Scientific.
Underlying delivery rests on a centralized core-lab model: MRI centers transmit DICOM images to NeuroRx, which standardizes, analyzes, and returns quantitative endpoints to sponsors under validated protocols. The combination of regulatory compliance, multi-decade protocol experience, and proprietary tooling constitutes the primary basis of competition. Constraints evident in the data include absence of disclosed revenue, no named customer logos, no funding history, and limited public information on headcount trends — leaving financial scale to be inferred from the 101–250 employee band and CRO revenue-per-employee benchmarks.
NeuroRx firmographics
Firmographics- Name
- NeuroRx
- Legal name
- NeuroRx Research
- Website
- https://neurorx.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- NeuroRx Research is a Montreal-based imaging contract research organization that provides centralized MRI analysis services for multicenter clinical trials, primarily in multiple sclerosis and neurological diseases, serving pharmaceutical sponsors globally and operating as a subsidiary of Clario since 2025.
- Ownership category
- akta.pro rank
NeuroRx industry classification
Industry- Product category
- Clinical Research Services (Imaging CRO)
- NAICS
- Medical and Diagnostic Laboratories (6215), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Multiple Sclerosis & Neuroimmunology (HLAKAIAF)
- akta.pro secondary industry
- General Neurology (HLAKAIAA)
Keywords
Where NeuroRx is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
NeuroRx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Clinical Trial MRI Analysis Services: NeuroRx provides professional management of all MRI-related study activities as a contract research organization. Revenue is generated through service contracts with pharmaceutical sponsors conducting clinical trials. Services include MRI protocol assistance, analysis, reporting, and data transfer.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
NeuroRx product offering
Product offeringCore offering
NeuroRx provides centralized MRI image analysis services for pharmaceutical sponsors conducting multicenter clinical trials, with a specialization in multiple sclerosis and other neurological diseases. Services cover the full lifecycle of MRI-related trial activities including protocol assistance, scan tracking, site setup and supervision, advanced 3D image analysis with automatic segmentation, regulatory-compliant data management, and regular reporting. All work is performed in an ICH-GCP and 21CFR Part 11 compliant environment using proprietary quantitative imaging techniques.
Product overview
NeuroRx is an imaging Contract Research Organization (CRO) that provides comprehensive, fully integrated MRI analysis services for multicenter clinical trials, primarily focused on multiple sclerosis and other neurological diseases. The company operates as a single unified service offering centered around MRI analysis, with integrated components including the NeuroRx Scan Tracking Tool (NTT) for scan logistics management, the NeuroRx Database (NFD) for validated data storage, MRI Protocol Assistance, Site Setup and Supervision, and Regular Reporting Services. All services are delivered in an ICH-GCP and 21CFR Part 11 compliant environment using advanced quantitative imaging techniques including 3D analysis, automatic segmentation with expert oversight, and specialized non-conventional MRI techniques (MTR and MRS). NeuroRx has been acquired by Clario and now operates as part of Clario's neuroscience therapeutic area.
Differentiator
Problem solved
Functional benefit
Products and services
- MRI Analysis Services
Quantifiable outcome
- Maximize study power through precise MRI outcome data
Companies that use NeuroRx
Customer profileSegments1 record
Ideal customer profiles1 record
NeuroRx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature6 records
NeuroRx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ClariomajorNeuroRx has been acquired by Clario, forming a strategic partnership that combines NeuroRx's specialized MRI analysis expertise for multiple sclerosis with Clario's broader clinical trial data solutions. Clario announced an $8.9 billion bid by Thermo Fisher Scientific, indicating significant strategic value. The integration positions NeuroRx's imaging CRO capabilities within Clario's global clinical research infrastructure.
Scale indicators1 record
Recent moves4 records
Expansion highlights5 records
NeuroRx competitors and assessment
Company assessmentDirect peers
- Ixico: UK-based imaging contract research organization providing MRI and other imaging analysis services for clinical trials in neurological diseases, including multiple sclerosis. Directly comparable to NeuroRx on modality, therapeutic-area focus, and sponsor customer base.
- Invicro: Imaging CRO offering quantitative MRI, PET, and image analysis services for clinical trials across neurology and oncology. Comparable to NeuroRx in providing trial-grade imaging biomarker services to pharmaceutical sponsors, with broader modality coverage.
- Signant Health: Clinical technology provider offering imaging, eCOA, and other clinical outcome assessments for CNS and other therapeutic-area trials. Directly comparable to NeuroRx on the imaging-endpoint side of neuroscience trials, with additional adjacent capabilities.
Broad incumbents
- Clario: Global clinical trial data and technology company, now the parent of NeuroRx, offering imaging, eCOA, cardiac safety, and respiratory solutions. Overlaps with NeuroRx through its imaging services and broader neuroscience therapeutic area, but at much larger scale and scope.
- IQVIA: One of the world's largest CROs with imaging and clinical data services spanning multiple therapeutic areas. Competes with NeuroRx for MS and neurology imaging endpoints, but offers a far broader end-to-end trial delivery platform.
- Parexel: Major global CRO providing full-service clinical development, including imaging analysis capabilities. Comparable as a buyer of MS and neurology trial work, with broader biopharmaceutical services than NeuroRx.
- Medpace: Mid-to-large CRO with full-service clinical trial execution including imaging management for sponsors. Overlaps NeuroRx's customer segment (pharma sponsors running multicenter trials) while operating a much broader delivery model.
- Worldwide Clinical Trials: Mid-sized global CRO with strong CNS/neurology franchise and imaging management for clinical trials. Comparable customer base (pharma sponsors) and therapeutic-area overlap (MS and neurology), with broader full-service CRO delivery.
- Charles River Laboratories: Large CRO and preclinical/research services provider with clinical imaging and biomarker capabilities. Overlaps NeuroRx at the clinical-trial imaging interface while operating across discovery, preclinical, and clinical stages.
Emerging players
- Cerveau Technologies: Provides tau PET imaging biomarkers and related imaging tools for neurodegenerative disease clinical trials, including Alzheimer's and other CNS indications. Comparable to NeuroRx as a neurology-focused imaging partner, but specialized in PET rather than MRI.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
NeuroRx social profiles
Digital presenceNeuroRx compliance and trust
Trust signalCompliance3 records
NeuroRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroRx leadership team
Management profileNumber of profiles
NeuroRx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroRx
What does NeuroRx do?
NeuroRx provides centralized MRI image analysis services for pharmaceutical sponsors conducting multicenter clinical trials, with a specialization in multiple sclerosis and other neurological diseases. Services cover the full lifecycle of MRI-related trial activities including protocol assistance, scan tracking, site setup and supervision, advanced 3D image analysis with automatic segmentation, regulatory-compliant data management, and regular reporting. All work is performed in an ICH-GCP and 21CFR Part 11 compliant environment using proprietary quantitative imaging techniques.
Is NeuroRx a public or private company?
NeuroRx is a private company. It is classified as corporate owned and is currently acquired.
When was NeuroRx founded?
NeuroRx was founded in 2002. It employs 101 to 250 people.
Where is NeuroRx based?
NeuroRx is headquartered in Montréal, Canada, in the North America region.
How does NeuroRx make money?
One revenue line is on record: clinical Trial MRI Analysis Services.
Who are NeuroRx's main competitors?
Direct peers on record are Ixico, Invicro and Signant Health. Broad incumbents are Clario, IQVIA, Parexel, Medpace, Worldwide Clinical Trials and Charles River Laboratories. Cerveau Technologies is listed as an emerging player.
Does NeuroRx have an API?
No public API is recorded for NeuroRx.
What industry is NeuroRx in?
NeuroRx's product category is Clinical Research Services (Imaging CRO). Its primary akta.pro industry code is HLAKAIAF, Multiple Sclerosis & Neuroimmunology, with a secondary code of HLAKAIAA, General Neurology. Its NAICS code is 6215 and its SIC code is 8731.